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Abstract 
Cutaneous adverse drug reactions (CADRs) in patients with psychotropic drugs are common. 
Large studies on the relevant drugs and other risk factors are still scarce. 
594 cases of severe CADRs (“cases”) were compared with 8085 cases of other adverse drug 
reactions (“non-cases”) documented in a pharmacovigilance program in psychiatry (AMSP) from 
1993 to 2014. Logistic regression was carried out to determine risk factors and between-drug 
differences. 
CADRs were relatively more prevalent in patients treated with clomipramine, maprotiline, car- 
bamazepine, lamotrigine, acamprosate, clomethiazole and disulﬁram as well as with antide- 
pressants and anticonvulsants as drug classes ( p < 0.01). For these drugs, signiﬁcantly more 
women were found in patients using maprotiline, lamotrigine (not carbamazepine) and in the 
groups of antidepressants, tricyclics and anticonvulsants ( p < 0.01). Women were more vulner- 
able to CADRs (67% in cases and 56% in non-cases, p < 0.01). The signiﬁcantly higher rate of 
CADRs in women was mainly observed under age of 50 years, i.e. during female reproductive 
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years. In a multivariate logistic regression, female sex, the diagnostic group ICD F1 (substance 
abuse), maprotiline, carbamazepine, lamotrigine and clomethiazole were identiﬁed as risk fac- 
tors of CADRs. 
The case/non-case approach allowed to identify risk factors based on empirical data rather 
than experts’ evaluations. The new ﬁndings of substance abuse and clomethiazole as risk fac- 
tors for CADRs have to be conﬁrmed in further studies. Since CADRs can be life-threatening, it 
is important to be aware of risk factors, especially women during their reproductive period and 
with lamotrigine treatment. 
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC 
BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
Although the true incidence of adverse drug reactions
(ADRs) is difﬁcult to determine, there is evidence that cu-
taneous adverse drug reactions (CADRs) are among the most
frequently observed adverse reactions to drugs ( Svensson
et al., 2001 ). CADRs account for 10–20% of all reported
ADRs ( Faich et al., 1987; van der Linden et al., 1998 ).
These reactions may range from mildly discomforting ex-
anthematous skin rashes to severe, life-threatening event
like toxic epidermal necrolysis (TEN). The most severe and
life-threatening types of CADRs consist of erythema mul-
tiforme, urticaria, drug-induced hypersensitivity syndrome
(DIHS) also referred to as drug reaction with eosinophilia
and systemic symptoms (DRESS), and epidermal necrolysis -
including Stevens-Johnson syndrome (SJS) and TEN ( Mitkov
et al., 2014 ). 
In hospitalized patients, the incidence of CADRs ranges
from 1% to 3% ( Arndt and Jick, 1976; Bigby et al., 1986 ),
whereas the incidence of CADRs in patients taking psy-
chotropic medications has been estimated as being approx-
imately 2–5% ( Kimyai-Asadi et al., 1999 ). Due to possibly
higher incidence of CADRs to psychotropic medications and
potentially life-threatening reactions, it is clinically impor-
tant to investigate cause and risk factors of CADRs to psy-
chotropic medications. 
The causality assessment varies among reported studies
and is limited by the ethical constraints of re-challenging
patients with a drug that may evoke a life-threatening or
seriously disabling reaction ( Svensson et al., 2001 ). Some
risk factors, including female sex ( Bigby et al., 1986; Naldi
et al., 1999; Fattinger et al., 2000; Alvestad et al., 2007;
Wang et al., 2012 ), greater age ( Naldi et al., 1999; Warnock
and Morris, 2002 ) and HLA-B ∗5801 and HLA-A ∗3101 subtype
( McCormack et al., 2011 ) have been identiﬁed to be asso-
ciated with CADRs. Despite of the high clinical relevance of
CADRs, large scale studies identifying drugs prone to such
effects, along with predictive risk factors are still rare. 
In this paper we analyzed the ADR data provided by the
international Drug Safety Program in Psychiatry (Arzneimit-
telsicherheit in der Psychiatrie, AMSP). The previous study
of Lange-Asschenfeldt et al. (2009) with AMSP data from
1993–2005 about CADRs had its focus on the reported in-
cidence rates of severe CADRs to psychiatric drugs and was
based on probability ratings of causality by experts ( Lange-
Asschenfeldt et al., 2009 ). In this previous study, there
were 214 cases of severe CADRs of psychotropic drugs in- cluding mood stabilizing anticonvulsants. Exanthems consti-
tuted the majority of the recorded severe CADRs. The most
common symptom was pruritus (50%), followed by edema
(12%). The median clinical latency was below 10 days for
all subtypes. Life-threatening CADRs amounted to 3% of the
CADR cases. Immediate drug discontinuation was the direct
measure in the vast majority of cases (about 95%). Drug
treatment involved antihistamine (about 50%) and steroids
(35.0%). 
In the present study we analyzed a larger dataset from
1993–2014. Speciﬁcally, we aimed to identify new possible
causes and risk factors through a case control design and
multivariate regression. Thus we applied an empirical ap-
proach that allows us to be as independent of experts’ deci-
sion as possible. A previous report in the literature has sug-
gested that women in their reproductive years have a higher
incidence rate of CADRs than men because of their more
reactive immune system ( Alvestad et al., 2007 ). There-
fore, our study addressed the questions of (1) the extent
to which the relative CADR rates differ between males and
females; (2) the inﬂuence of age; (3) potential between-
drug differences; and (4) risk factors that may predict
CADRs. 
2. Experimental procedures 
2.1. Data source 
The adverse drug reaction (ADR) dataset in the present
study was collected through AMSP since 1993. AMSP is an
ongoing international multicenter drug safety surveillance
program that systematically collects data on psychophar-
macotherapy and ADRs from more than 100 psychiatric hos-
pitals in the German speaking countries (Germany, Austria
and Switzerland). The underlying method of the project
has been described in detail by various previous publica-
tions ( Engel et al., 2004; Grohmann et al., 2004; Lange-
Asschenfeldt et al., 2009; Friedrich et al., 2016 ): data on
severe ADRs due to psychopharmacological treatment are
systematically assessed by the participating hospitals. ADRs
are regarded as “severe” when causing signiﬁcant impact on
the course of treatment (e.g., life-threatening or seriously
endangering health) or on the patients’ everyday function-
ing. The AMSP protocol provides speciﬁc guidelines for the
assessment of ADRs in relation to respective organ system,
for example, CADRs is classiﬁed as severe when the whole
Cutaneous adverse drug reactions to psychotropic drugs 113 
b  
a  
i
a
a
d
f  
l
l
 
c
a
a
m
h
a
s
 
a
w
t  
e
l
p
o
d
2
A
(  
c
c
a  
A
d  
T
A  
i
l  
n  
o
i  
5
p  
i  
s  
i
R  
w  
w
e
 
c
t
m  
c  
1  
a  
r  
c  
a  
t
 
o  
n
2
I
t  
t
i
a  
F  
s
e  
c
f
r
n  
g
o  
c
w
3
T  
c  
s
T  
a  
d  
n  
o
M
c
t
p  
t
2
p  
(
 
f
d
3
1  
1  
c
 
W  
s  
pody or more than one body part is affected ( Grohmann et
l., 2014 ). For each adverse event, a detailed description
s documented along with the basic demographic, psychi- 
tric and somatic data (including all diagnoses). All cases 
re reviewed by a senior psychiatrist of each hospital and 
iscussed thereafter at case conferences. The probability 
or the ADR to be caused by a speciﬁc drug is rated as fol-
ows ( Grohmann et al., 2004 ). 
Possible : ADR unknown or alternative explanation more 
ikely. 
Probable : ADR known for drug in question and time-
ourse and dosage in accordance with previous experience; 
lternative explanation less likely. 
Deﬁnite : the same as “probable” together with reappear- 
nce after re-exposure with drug in question. 
Questionable : questionable or not sufﬁciently docu- 
ented. 
In addition, drug use was collected by all participating 
ospitals on two pre-speciﬁed reference days every year for 
ll inpatients. This prescription dataset was not used in this 
tudy. 
Our study included all ADR cases from 1993 to 2014 with
 probability rating of “deﬁnite”, “probable”, or “possible”
ith focus being laid on all concomitant drugs. By applying 
his method, our case control study is not limited by expert
valuations. 
The AMSP drug surveillance program was approved by the 
eading boards of each participating institute prior to im- 
lementation, and the Ethics Committee of the University 
f Munich formally approved evaluations based on the AMSP 
atabank. 
.2. Study design 
 nested case control design, i.e. case/non-case approach 
 Moore et al., 1997 ) was used to identify new possible
auses and risk factors of CADRs. CADRs were deﬁned as 
ases, and all other ADRs were regarded as non-cases. Cases 
nd non-cases were both derived from the ADR dataset of
MSP as described above. Reports were only included when 
ata were complete and patients were 18 years or older.
he ADR dataset under investigation was comprised of 9592 
DR reports. Of these, 474 cases were excluded because of
ncomplete information, and 439 cases because of skin re- 
ated ADRs - like edema, acne and hair loss - which were
ot classiﬁed as CADRs for the purpose of this study. Hence,
ur study was conducted with 8679 ADR reports, represent- 
ng 90.48% of the total available ADR reports. We identiﬁed
94 (6.84%) CADR cases and 8085 non-cases (93.16%). Re- 
orting odds ratio (ROR) of ADR is the ratio of the report-
ng odd of the association between the CADR and the expo-
ure of the interest. ROR is a measure of disproportionality
n case/non-case approach ( van Puijenbroek et al., 2002; 
othman et al., 2004 ). The ROR and its conﬁdence intervals
ere computed as described in Moore et al. (1997) . RORs
hose conﬁdence interval did not include 1 were consid- 
red as signiﬁcantly different from 1. 
If the ROR is greater than 1 as deﬁned above, then it
an be interpreted as indicating an association between 
he exposure and reporting of the reaction of interest. This 
ethod can be regarded as a variant of the database nestedase-control method ( Kramer et al., 1988 ; Strom et al.,
994 ). Exposure to a certain drug or drug class was deﬁned
s the presence of the drug or drug class of interest in a
eport, independently of whether or not the drug or drug
lass was suspected of causing the reaction. In addition, di-
gnostic groups and gender were investigated by means of
he same method. 
In the next step, we calculated and compared the ratios
f female to male among different age groups for cases and
on-cases. 
.3. Data analysis/statistics 
n case/non-case approach, Student’s t test was performed 
o assess the signiﬁcance of differences in the mean of con-
inuous variables between cases and non-cases. Differences 
n the proportions of the characteristics between cases 
nd non-cases were tested for signiﬁcance with χ2 test or
isher’s exact test where appropriate. The strength of as-
ociation between the exposure of interest and CADR was 
xpressed as ROR with 95% conﬁdence intervals. First, we
onducted standard univariate analysis of ROR for several 
actors. Subsequently, these RORs were adjusted for age, 
eporting time period, hospital, number of diagnoses and 
umber of concomitant drugs by means of multivariate lo-
istic regression analysis. Finally, 95% conﬁdence intervals 
f the resulting female-male ratios (by age groups) were
alculated and compared between cases and non-cases. 
All statistical calculations were performed using SAS soft- 
are (Statistical Analysis System, version 9.3). 
. Results 
he sample under investigation was comprised of 594 CADR
ases and 8085 non-cases exhibiting other ADRs. Table 1
hows the basic characteristics of cases versus non-cases. 
here were signiﬁcantly more female patients ( p < 0.001)
mong the cases compared to the non-cases. Despite the
ifferences in the sample composition, there was no sig-
iﬁcant difference in terms of mean age or mean number
f concomitant medication between cases and non-cases. 
oreover, no signiﬁcant difference showed up between 
ases and non-cases regarding monotherapy, combination 
herapy and polypharmacy. To determine if the reporting 
eriod might play a role, we divided the observation in-
erval into three periods: 1993–2000, 2001–2007 and 2008–
014. Interestingly, there were signiﬁcantly fewer cases re- 
orted than non-cases during the most recent time period
 p < 0.001). 
Table 2 shows the diagnostic groups (according to ICD 10)
or cases and non-cases. Mental and behavioral disorders 
ue to psychoactive substance use (ROR 2.64; 95% CI 2.21–
.15), mood [affective] disorders (ROR 1.43; 95% CI 1.21–
.69) and disorders of adult personality and behavior (ROR
.47; 95% CI 1.11–1.94) were the diagnostic groups signiﬁ-
antly more involved in cases. 
Table 3 shows the drug classes for cases and non-cases.
e found a signiﬁcant increase of RORs under antidepres-
ants (AD: ROR 1.25; 95% CI 1.04–1.49), tricyclic antide-
ressants (TCA: ROR 1.43; 95% CI 1.14–1.79), antiepileptic 
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Table 1 Characteristics of cases and non-cases. 
Cases Non-cases P value 
N = 594 N = 8085 
Mean age ( ± S.D.) 47.12 ( ± 16.19) 48.45 ( ± 18.89) NS 
Female ∗∗ 395 (66.50%) 4,521 (55.92%) < 0.001 
Mean No. of medication ( ± S.D.) 3.88 ( ± 2.23) 3.97 ( ± 2.50) NS 
Medication 
Monotherapy 135 (22.73%) 1634 (20.21%) NS 
Combination therapy 177 (29.80%) 2426 (30.01%) NS 
Polypharmacy 282 (47.47%) 4025 (49.78%) NS 
Reporting year 
1993–2000 138 (23.23%) 1462 (18.08%) NS 
2001–2007 286 (48.15%) 3478 (43.02%) NS 
2008–2014 ∗∗ 170 (28.62%) 3145 (38.90%) < 0.001 
Monotherapy: one psychotropic drug; Combination therapy: two psychotropic drugs; Polyphar- 
macy: three or more psychotropic drugs. 
∗ p value < 0.05, NS: not signiﬁcant. 
∗∗ p value < 0.01. 
Table 2 Cases and non-cases per diagnosis group. 
Diagnosis group ICD10 ∗: deﬁnition Cases Non-cases ROR 
N = 594 N = 8085 (95% CI) 
F00-F09: organic, including symptomatic, mental disorders 46 (7.74%) 1045 (12.93%) 0.57 (0.42–0.77) 
F10-F19 ∗∗: mental and behavioral disorders due to psychoactive 
substance use 
212 (35.69%) 1406 (17.39%) 2.64 (2.21–3.15) 
F20-F29: schizophrenia, schizotypal and delusional disorders 137 (23.06%) 3351 (41.45%) 0.42 (0.35–0.52) 
F30-F39 ∗∗: mood [affective] disorders 300 (50.51%) 3372 (41.71%) 1.43 (1.21–1.69) 
F40-F48: neurotic, stress-related and somatoform disorders 73 (12.29%) 818 (10.12%) 1.25 (0.96–1.61) 
F50-F59: behavioral syndromes associated with physiological 
disturbances and physical factors 
6 (1.01%) 114 (1.41%) 0.71 (0.31–1.63) 
F60-F69 ∗∗: disorders of adult personality and behavior 60 (10.10%) 575 (7.11%) 1.47 (1.11–1.94) 
F70-F79: mental retardation 11 (1.85%) 208 (2.57%) 0.72 (0.39–1.32) 
The total is higher than 100% since there could be multiple diagnoses per patient. 
∗ With minimum of three cases of CADR. 
∗∗ ROR signiﬁcantly greater than 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 drugs (AEP: ROR 3.30; 95% CI 2.79–3.90) and other psy-
chotropic drugs (including acamprosate, clomethiazole and
disulﬁram; ROR 6.13; 95% CI 3.99–9.42). 
Table 4 compares cases and non-cases for single drugs.
Comparing CADRs to the other ADRs, clomipramine (ROR
1.86; 95% CI 1.15–3.03), maprotiline (ROR 1.22; 95% CI 2.26–
4.19), carbamazepine (ROR 6.83; 95% CI 5.52–8.44), lam-
otrigine (ROR 4.14; 95% CI 3.01–5.68), clomethiazole (ROR
6.77 95% CI 4.13–11.09), acamprosate (ROR 4.56; 95% CI
1.23–16.87; only three CADRs) and disulﬁram (ROR 4.10; 95%
CI 1.13–14.94; only three CADRs) showed signiﬁcantly more
cases than non-cases. 
Table 5 shows the percentage of females for relevant drug
classes and for those drugs that were related to increased
numbers of cases ( Table 4 ). AD, TCA, AEP, maprotiline and
lamotrigine were signiﬁcantly more often prescribed in fe-
males among cases than among non-cases. 
Our multivariate logistic regression model included the
following variables: gender, age, time period, reporting
hospital, number of diagnoses and number of concomitant
drugs along with variables for diagnostic groups and medi-
cations. This model identiﬁed female sex, diagnoses F10-19(substance abuse), maprotiline, carbamazepine, lamotrig-
ine and clomethiazole as signiﬁcant risk factors of CADRs
( Table 6 ). 
The time-to-onset ( Fig. 1 ) had a median value of 6 days
in cases and 10 days in non-cases. The mean value was 17
( ± S.D. 127.4) days in the cases and 59 ( ± S.D. 301.8) days
in the non-cases (not signiﬁcant). 
Fig. 2 shows the female-male ratios in CADRs stratiﬁed
by age groups compared with non-cases. For the age groups
18–30, 31–40 and 41–50 years, female-male ratios were sig-
niﬁcantly higher in CADRs than in non-cases. This signiﬁcant
difference was not present in the higher age groups 51–60
and 61–70. The mean relative female-male ratio was 1.7 in
the age group 18–50 and 1.24 in the age group 51–70. 
4. Discussion 
In this case-control study, 594 patients suffering from se-
vere CADRs (cases) were compared with 8085 patients suf-
fering from other severe ADRs (non-cases) as documented in
a large pharmacovigilance program. The CADR cases were
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Table 3 Cases and non-cases per drug class. 
Drug 
class ∗
Cases Non-cases ROR 
N = 594 N = 8085 (95% CI) 
AD ∗∗ 411 (69.19%) 5,197 (64.28%) 1.25 (1.04–1.49) 
TCAs ∗∗ 98 (16.50%) 980 (12.12%) 1.43 (1.14–1.79) 
SSRIs 132 (22.22%) 1658 (20.51%) 1.11 (0.91–1.35) 
SNRIs 67 (11.28%) 995 (12.31%) 0.91 (0.70–1.18) 
NaSSAs 67 (11.28%) 1015 (12.55%) 0.89 (0.68–1.15) 
MAOIs 13 (2.19%) 116 (1.43%) 1.54 (0.86–2.74) 
OADs 34 (5.72%) 442 (5.47%) 1.05 (0.73–1.50) 
AEP ∗∗ 285 (47.98%) 1766 (21.84%) 3.30 (2.79–3.90) 
Lithium 47 (7.91%) 656 (8.11%) 0.97 (0.72–1.33) 
Anti-parkinson drugs 43 (7.24%) 690 (8.53%) 0.84 (0.61–1.15) 
Hypnotics 74 (12.46%) 889 (11.00%) 1.15 (0.89–1.48) 
BZDs 200 (33.67%) 2867 (35.46%) 0.92 (0.78–1.10) 
Z-drugs 43 (7.24%) 641 (7.93%) 0.91 (0.66–1.25) 
Antipsychotics 458 (77.10%) 9385 (116.08%) 0.66 (0.59–0.75) 
Typical antipsychotics 102 (17.17%) 2126 (26.30%) 0.76 (0.66–0.89) 
Atypical antipsychotics 234 (39.39%) 5603 (69.30%) 0.29 (0.24–0.34) 
Antidementia drugs 14 (2.36%) 252 (3.12%) 0.75 (0.44–1.29) 
Tranquillizers 185 (31.14%) 2666 (32.97%) 0.92 (0.77–1.10) 
Others ∗∗ 31 (5.22%) 72 (0.89%) 6.13 (3.99–9.42) 
AEP: antiepileptic; AD: antidepressant; TCAs: tricyclic antidepressants; SSRIs: selective serotonin reuptake inhibitors; 
SNRIs: selective Serotonin–norepinephrine reuptake inhibitors; NaSSAs: noradrenergic and speciﬁc serotonergic an- 
tidepressants; MAOIs: monoamine oxidase inhibitors; OADs: other ADs, including agomelatin, bupoprion, nefazodone, 
reboxetine, tianeptine and trazodone; BZDs: benzodiazepine derivatives; Z-drugs: zopiclone, zopidem and zaleplon; 
others: acamprosate, clomethiazole, disulﬁram. 
∗ With a minimum of three cases of CADR, 
∗∗ ROR signiﬁcantly greater than 1. 
Table 4 Cases and non-cases per relevant single drug. 
Medication ∗ Cases (%) Non-cases (%) ROR 
N = 594 N = 8085 (95% CI) 
TCA 
Amitriptyline 15 (2.53%) 248 (3.07%) 0.82 (0.48–1.39) 
Clomipramine ∗∗ 19 (3.20%) 141 (1.74%) 1.86 (1.15–3.03) 
Dibenzepine 3 (0.51%) 21 (0.26%) 1.95 (0.58–6.56) 
Doxepine 15 (2.53%) 154 (1.90%) 1.34 (0.78–2.28) 
Maprotiline ∗∗ 12 (2.02%) 73 (0.90%) 1.22 (2.26–4.19) 
Nortriptyline 6 (1.01%) 66 (0.82%) 1.24 (0.54–2.87) 
Trimipramine 24 (4.04%) 224 (2.77%) 1.48 (0.96–2.27) 
AEP 
Carbamazepine ∗∗ 149 (25.08%) 378 (4.68%) 6.83 (5.52–8.44) 
Clonazepam 5 (0.84%) 99 (1.22%) 0.69 (0.28–1.69) 
Gabapentin 7 (1.18%) 47 (0.58%) 2.04 (0.92–4.53) 
Lamotrigine ∗∗ 53 (8.92%) 187 (2.31%) 4.14 (3.01–5.68) 
Oxcarbazepine 10 (1.68%) 93 (1.15%) 1.47 (0.76–2.84) 
Pregabalin 7 (1.18%) 168 (2.08%) 0.56 (0.26–1.20) 
Valproate 47 (7.91%) 674 (8.34%) 0.95 (0.69–1.29) 
Others 
Acamprosate ∗∗ 3 (0.51%) 9 (0.11%) 4.56 (1.23–16.87) 
Clomethiazole ∗∗ 24 (4.04%) 50 (0.62%) 6.77 (4.13–11.09) 
Disulﬁram ∗∗ 3 (0.51%) 10 (0.12%) 4.10 (1.13–14.94) 
TCAs: tricyclic antidepressants; AEP: antiepileptic; Others: acamprosate, clomethiazole, disulﬁram. 
∗ With a minimum of three cases of CADRs from signiﬁcant drug groups in Table 4 , maprotiline is classiﬁed here as 
TCA. 
∗∗ ROR signiﬁcantly greater than 1. 
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Table 5 Percentage of females in cases and non-cases per relevant prescribed drug class and single drug. 
Cases (%) Non-cases (%) P value 
N = 594 N = 8085 
Female (%) ∗∗ 395 (66.50%) 4521 (55.92%) < 0.001 
AD ∗∗ 74.94% 67.73% 0.0025 
TCA ∗∗ 79.59% 60.39% 0.0078 
Clomipramine 73.68% 61.41% NS 
Maprotiline ∗∗ 75.00% 66.22% 0.0055 
AEP ∗∗ 64.91% 53.79% < 0.001 
Carbamazepine 54.36% 55.82% NS 
Lamotrigine ∗∗ 88.68% 64.71% < 0.001 
Others 22.58% 34.29% NS 
Acamprosate 33.33% 33.33% NS 
Clomethiazole 16.67% 30.00% NS 
Disulﬁram 33.33% 20.00% NS 
AD: antidepressants; TCAs: tricyclic antidepressants; AEP: antiepileptics; Others: acamprosate, clomethiazole, 
disulﬁram. 
∗ p value < 0.05. 
∗∗ p value < 0.01. 
Table 6 Factors correlated with CADRs according to logistic regression. 
Cases (%) Non-cases (%) Unadjusted ROR (95% CI) Adjusted a ROR (95% CI) P value 
N = 594 N = 8085 
Female ∗∗ 395 (66.50%) 4521 (55.92%) 1.57 (1.31–1.87) 1.75 (1.43–2.13) < 0.001 
Diagnosis group 
F00-F09 46 (7.74%) 1045 (12.93%) 0.57 (0.42–0.77) 0.53 (0.32–0.87) 0.0127 
F10-F19 ∗∗ 212 (35.69%) 1406 (17.39%) 2.64 (2.21–3.15) 1.68 (1.15–2.45) 0.0073 
F20-F29 137 (23.06%) 3351 (41.45%) 0.42 (0.35–0.52) 0.38 (0.26–0.56) < 0.001 
F30-F39 300 (50.51%) 3372 (41.71%) 1.43 (1.21–1.69) 0.80 (0.56–1.15) NS 
F40-F49 73 (12.29%) 818 (10.12%) 1.25 (0.96–1.61) 0.89 (0.60–1.33) NS 
F50-F59 6 (1.01%) 114 (1.41%) 0.71 (0.31–1.63) 0.48 (0.20–1.18) NS 
F60-F69 60 (10.10%) 575 (7.11%) 1.47 (1.11–1.94) 0.82 (0.54–1.25) NS 
F70-F79 11 (1.85%) 208 (2.57%) 0.72 (0.39–1.32) 0.60 (0.29–1.26) NS 
Medications 
Clomipramine 19 (3.20%) 141 (1.74%) 1.86 (1.15–3.03) 1.35 (0.79–2.32) NS 
Maprotiline ∗ 12 (2.02%) 73 (0.90%) 1.22 (2.26–4.19) 2.11 (1.09–4.10) 0.0270 
Carbamazepine ∗∗ 149 (25.08%) 378 (4.68%) 6.83 (5.52–8.44) 5.72 (4.45–7.37) < 0.001 
Lamotrigine ∗∗ 53 (8.92%) 187 (2.31%) 4.14 (3.01–5.68) 6.05 (4.20–8.72) < 0.001 
Acamprosate 3 (0.51%) 9 (0.11%) 4.56 (1.23–6.87) 2.70 (0.65–11.24) NS 
Clomethiazole ∗∗ 24 (4.04%) 50 (0.62%) 6.77 (4.13–1.09) 2.34 (1.27–4.33) 0.0066 
Disulﬁram 3 (0.51%) 10 (0.12%) 4.10 (1.13–4.94) 3.32(0.81–13.59) NS 
a adjustment was made for age, reporting years, reporting hospital, number of diagnosis and number of concomitant 
drugs. Adjusted R 2 of the regression model was 20.81%. 
∗ p value < 0.05 and ROR greater than 1. 
∗∗ p value < 0.01 and ROR greater than 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.8% of all ADR cases, suggesting that CADR was rather fre-
quently associated with psychotropic drugs. In the most re-
cent period from 2007 to 2014, the percentage of CADR
cases was lower (5.1%). The case/non-case approach with a
multivariate logistic regression analysis allowed us to iden-
tify inﬂuencing factors without limited by experts’ opinions.
4.1. Age/sex difference 
Greater age has been associated with CADRs in general
( Naldi et al., 1999 ) or with CADRs to antidepressants( Warnock and Morris, 2002 ). In our case/non-case analysis,
the result showed that there was no signiﬁcant difference
of mean age between CADRs and other ADRs. This could
be due to the nature of case/non-case analysis, since the
case/non-case method compares different ADRs within the
same dataset. Therefore, a risk factor generally associated
to all ADRs cannot be found by this approach. 
The generally higher risk of women developing adverse
drug reactions is described for various adverse drug re-
actions ( Fattinger et al., 2000; Pirmohamed et al., 2004;
Patel et al., 2007; Franconi and Campesi, 2014 ), but could
not be found in all studies ( D’Incau et al., 2014 ). Regarding
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Figure 1 Frequency of time-to-onset of ADRs in case and non-case. 
Figure 2 Female-male ratios of CADRs stratiﬁed by age groups. 
∗ age groups with female-male ratio signiﬁcantly greater than 1. 
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iADRs, a sex difference with higher incidence in women in 
eneral ( Bigby et al., 1986; Naldi et al., 1999 ) or only for
ertain drug groups ( Alvestad et al., 2007; Lange- 
sschenfeldt et al., 2009; Wang et al., 2012 ) was found, but
ould not be shown in other studies ( Li and Ma, 2006; Hirsch
t al., 2006 ). Our results show that women (56%) predom-
nated in non-cases, but the sex difference was more ap-
arent in cases (67%). There were signiﬁcantly more female 
atients ( p < 0.001) in cases than non-cases, which clearlyemonstrates that sex difference is particularly important 
or CADRs. 
.2. Polypharmacy 
etween cases and non-cases, we did not ﬁnd signiﬁcant
ifference in terms of mean number of concomitant med-
cation, proportion of monotherapy, combination therapy 
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 and polypharmacy. In contrast, previous studies using differ-
ent methods have identiﬁed polypharmacy as a risk factor
for many clinically relevant ADRs ( Fattinger et al., 2000 ).
The discrepancy could be due to the nature of the ap-
proach, since case/non-case method compares different
ADRs within one dataset. There are also contradicting ﬁnd-
ings whether polypharmacy is a risk factor of CADRs to
psychotropic drugs. It has been identiﬁed as risk factor of
CADRs to antidepressants ( Warnock and Morris, 2002 ) and to
mood stabilizers, especially the combination of lamotrigine
and valproate ( Warnock and Morris, 2003 ), whereas it was
not found for antiepileptics in another study ( Wang et al.,
2012 ). Further research regarding polypharmacy of differ-
ent drug classes and combinations as risk factor of CADRs is
needed. 
4.3. Reporting time period 
We divided the reporting years into three groups: 1993–
2000, 2001–2007 and 2008–2014. There was a signiﬁcant
difference between reporting of cases and non-cases dur-
ing 2008–2014 ( p < 0.01). During the latest time period, re-
ports of CADRs dropped about 40% as compared to the sec-
ond time period, while the reporting of other ADRs did
not decrease. This indicates a decrease of CADR cases over
time compared to other ADRs, presumably caused by differ-
ent prescribing patterns with less frequent prescriptions of
CADR related drugs ( Tables 3 and 4 ), e.g. lower prescription
rate of carbamazepine ( Druschky et al., 2018 ) and tricyclic
antidepressant drugs ( Stübner et al., 2018 ) in the more re-
cent years. 
4.4. Time-to-onset 
The time period between initiation of drug treatment and
the onset of ADRs (time-to-onset) is clinically important.
We found an average time-to-onset of 17 days in cases and
59 days in non-cases (not signiﬁcant). The median time-to-
onset was 6 days in cases and 10 days in non-cases. CADRs
appeared to occur slightly earlier than the rest of the ADRs.
4.5. Medication 
There have been several studies on CADRs to psychotropic
drugs, especially regarding antiepileptic and antidepres-
sant drugs ( Warnock and Morris, 2002 , 2003; Alvestad et
al., 2007; Amsterdam et al., 2009; Wang et al., 2012 ). In
the present study, we found clomipramine, maprotiline (tri-
cyclic antidepressants and also the overall group of antide-
pressants), carbamazepine and lamotrigine (and antiepilep-
tics in general) to be positively associated with CADRs. Our
results are accordant with previous studies ( Warnock and
Morris, 2002 , 2003; Alvestad et al., 2007; Wang et al., 2012 ).
In addition, we found that acamprosate, clomethiazole and
disulﬁram (and thus also the group of “other psychotropic
drugs”) were signiﬁcantly more involved in CADR cases. It
is remarkable that these three drugs prescribed preferably
in alcohol abuse were associated with CADRs. These sub-
stances are not only structurally different, but also used forvery different therapeutic purposes, e.g. for the treatment
of delirium (clomethiazole), as an anti-craving substance
(acamprosate) or as withdrawal / aversion therapy (disul-
ﬁram). This may indicate that the diagnosis itself (F1) could
be the underlying risk factor. 
4.6. Diagnosis 
Consecutively, we examined the relationship between di-
agnosis and CADRs. Interestingly, we found that F1 (men-
tal and behavioral disorders due to psychoactive substance
use), F3 (mood [affective] disorders) and F6 (disorders of
adult personality and behavior) according to ICD 10 were
more prevalent in patients with CADRs compared to other
ADRs. To decide whether the diagnostic group or the re-
spective medication was more relevant for CADRs, a logistic
regression was performed (see below). 
4.7. Relation of medication, sex and age 
For drugs that were signiﬁcantly more involved in cases than
non-cases, sex differences were calculated. Our analyses
found signiﬁcant sex differences for tricyclic antidepres-
sants, for antidepressant drugs generally, for antiepileptics
generally and for lamotrigine (but not for carbamazepine).
Consistently, previous studies from AMSP reported higher
incidence of CADRs in woman using antiepileptic drugs
( Lange-Asschenfeldt et al., 2009 ) and lamotrigine speciﬁ-
cally ( Druschky et al., 2018 ). 
Remarkably, the relative rates of CADRs of female to male
were larger than 1 in the age groups between 18 and 50.
In contrast, there was no statistically signiﬁcant sex differ-
ence in higher age groups. While in the reproductive age
group there were 70% more women than men, in the higher
age group there were only 24% more women. Female sex
has been identiﬁed as a risk factor of CADR in many pre-
vious publications ( Bigby et al., 1986; Naldi et al., 1999;
Fattinger et al., 2000; Alvestad et al., 2007; Wang et al.,
2012 ), but only one previous study also showed that females
are at higher risk of CADRs only during reproductive years
( Alvestad et al., 2007 ). This interaction between age and
sex might be explained with sex hormones during reproduc-
tive years and their effects on the immune system. 
There are several known pathomechanisms for CADRs.
Some are the result of non-immunological causes such as cu-
mulative toxicity, photosensitivity or interaction with other
drugs, while others are immune-mediated reactions such as
allergic reactions ( Marzano et al., 2016 ). Women have been
considered “immune-privileged” due to the sex hormones
( Gieﬁng-Kröll, 2015 ). The female sex steroid hormones en-
hance the innate immune responses in both physiological
and pathological states, whereas androgens mainly suppress
them ( Da Silva, 1999; Gieﬁng-Kröll, 2015 ). For example, re-
sponses to various types of vaccination are often higher in
women ( Cook, 2008 ) and a similar shift to female predom-
inance is reported for asthma, atopic conditions and hay
fever during reproductive years ( Shamssain and Shamsian,
1999; Osman, 2003 ). It has been discussed that women lose
their immunological “advantage” after menopause based
Cutaneous adverse drug reactions to psychotropic drugs 119 
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fn epidemiological data, and hormone replacement ther- 
py (HRT) shows beneﬁcial effects on the immune system 
 Gieﬁng-Kröll, 2015 ). 
.8. Factors according to the multivariate logistic 
egression 
ur multivariate analysis demonstrated that sex (female), 
iagnostic group (F1 substance abuse), maprotiline, carba- 
azepine and lamotrigine as well as clomethiazole were in- 
ependent risk factors in CADR cases with adjustment for 
ge, reporting years, reporting hospital, diagnostic groups 
nd medications. To our knowledge, we for the ﬁrst time
emonstrated that substance abuse and clomethiazole were 
ssociated with CADRs after controlling for possibly con- 
ounding factors. Previously, a report of toxic epidermal 
ecrolysis as ADR of carbamazepine administration, heroin 
nd alcohol abuse was published ( Petter and Haustein, 
999 ). Furthermore, another case-control study identiﬁed 
lcohol abuse as the only risk factor for carbamazepine–
nduced serious mucocutaneous adverse reactions using 
ultivariate regression ( Bertulyte et al., 2014 ). Whether 
ubstance abuse (especially alcohol) alters immunity and 
ubsequently increases susceptibility to CADRs needs to be 
urther investigated. Consistently, a case of severe allergic 
eaction to clomethiazole has been reported ( Khan, 1976 ).
owever, the case report was discussed brieﬂy after that 
he allergic reaction might have been caused by the coloring
gent tartrazine in the capsules of clomethiazole, not the 
rug itself ( Weeks, 1977 ), but another reply added one case
eport of allergic skin reaction to clomethiazole ( Halstead 
nd Madden, 1976 ). Taken together, the new ﬁndings en-
ourage to further explore the underlying mechanisms of 
ADRs possibly caused by substance abuse or by clomethia- 
ole. 
.9. Strength and limitation 
he method of case/non-case study has led to plausi- 
le and novel results. The ADRs with their prescriptions 
ere compared without taking the experts’ causality as- 
essment (“imputation”) into account. Prejudice, which is 
navoidable in imputation, e.g. due to technical informa- 
ion/package insert and to the state of literature, is elimi-
ated to some extent. 
The ROR is identical to the odds ratio calculated from
 case-control study that compares each drug to all other
rugs ( Rothman et al., 2004 ). An advantage of using ROR is
hat non-selective underreporting of a drug or ADR does not
ssentially inﬂuence the ROR. Underreporting is inevitable 
n spontaneous reporting ADR datasets. It has been sug- 
ested that underreporting is more or less of the same mag-
itude for all drugs and other exposures. Hence, it is possi-
le to identify differences in adverse effects of drugs from
omparison of their frequency within the same data source 
 Pierﬁtte et al., 1999 ). 
One of the disadvantages of the approach is that the asso-
iations in case/non-case study can be biased in some ways. 
he association of a drug and a single ADR in the analy-
is of spontaneous reports can be lessened if another re-ction speciﬁc to the drug is widely reported ( Moore et al.,
997 ). In our study, antipsychotics were underrepresented 
n CADRs ( Table 3 ). This could be due to the fact that an-
ipsychotics have other ADRs in the foreground, such as ex-
rapyramidal disorders or weight gain. On the other hand,
ery low incidence rates of CADRs of antipsychotics have
lso been reported previously ( Lange-Asschenfeldt et al., 
009 ). 
Another problem occurs in the selection of cases from a
pontaneous reporting database. In the AMSP study, drug 
onitors collect data on ADRs in association with psy-
hopharmacological treatment that occurred within these 
ospitals. The cases are then reviewed by a senior doctor
f each hospital and discussed thereafter at central case 
onference. We cannot rule out that CADRs have been de-
ected more often than some other ADRs such as clinically
elevant changes in laboratory values. On the other hand, a
ew CADR cases may have been missed because of the se-
ection criteria based on experts’ decision that the CADR
as to be related to the drug treatment. There could be
neven under-reporting among different drugs due to the 
ossible unrecognition of the reaction as drug-related. To 
lleviate the issue, the present study included all the ADR
ases with a probability rating of “possible ” or higher and all
he concomitant drugs of ADR cases were analyzed regard-
ess of whether the drugs were imputed or not. Therefore,
t is aligned with our goal of the evidence-based approach,
ince it is not limited only to the drugs imputed by experts.
evertheless, in a spontaneous reporting system, the under- 
nd selective reporting of ADRs is principally a serious prob-
em in quantifying ADRs in relation to drugs and other risk
actors. 
.10. Conclusion 
egarding time-to-onset, the CADRs seem to occur earlier 
han other ADRs covered by the AMSP project: median 6 days
ersus 10 days. Particularly at the beginning of the treat-
ent, CADR should be considered. 
Important risk factors of CADRs identiﬁed in this study
re: female sex (especially during reproductive age pe- 
iod), diagnostic group F1 (substance abuse) and the drugs
aprotiline, carbamazepine, lamotrigine and clomethia- 
ole. Since CADRs can be threatening, it is important to be
ware of these risk factors. In contrast to maprotiline, car-
amazepine and clomethiazole, lamotrigine still plays a ma- 
or role in psychiatric pharmacotherapy. Patients prescribed 
ith lamotrigine, especially females, should be informed 
bout CADRs and encouraged to observe themselves, and 
ll recommended and widely followed precautionary mea- 
ures should be strictly followed, e.g. slow increase in dos-
ng. In addition, this study indicates that substance abuse 
s an important risk factor for CADRs. So far, little atten-
ion has been paid to substance abuse (diagnosis group F1),
hich apparently favors the likelihood of CADRs to different
edications. 
By the case/non-case study with all prescriptions and re-
ated ADRs, novel relationships could be found that need
o be veriﬁed or falsiﬁed in further studies. In the present
tudy, substance abuse and clomethiazole identiﬁed as risk 
actors of CADRs are such novel ﬁndings. 
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